You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1725-ESGO Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer- results of a multicentre NOGGO phase I and II study (TOPAZ)

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1725-ESGO Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer- results of a multicentre NOGGO phase I and II study (TOPAZ)
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to October 2024

AbstractFullPdf
Oct 2022201
Nov 20225603
Dec 20226008
Jan 20231601
Feb 20231604
Mar 20232607
Apr 20232102
May 20233200
Jun 20231000
Jul 20231203
Aug 20231304
Sep 2023604
Oct 20231202
Nov 20232403
Dec 20232102
Jan 20241601
Feb 20241603
Mar 202418011
Apr 20241409
May 20241205
Jun 20241202
Jul 2024003
Aug 2024702
Sep 2024801
Oct 2024401
Total434082